Selected research
Industry Research
Ophthalmology Therapeutics Industry Research Report 2026
Market perspective
The global Ophthalmology Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ophthalmology Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ophthalmology Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ophthalmology Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ophthalmology Therapeutics include Teva Pharmaceutical Industries, Novartis AG, Pfizer, Santen Pharmaceutical, Bayer, AbbVie, Regeneron Pharmaceuticals, Otsuka Holdings and F. Hoffmann-La Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ophthalmology Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ophthalmology Therapeutics Market by Company
Teva Pharmaceutical Industries
Novartis AG
Pfizer
Santen Pharmaceutical
Bayer
AbbVie
Regeneron Pharmaceuticals
Otsuka Holdings
F. Hoffmann-La Roche
Aerie Pharmaceuticals
Ophthalmology Therapeutics Segment by Type
Ointments
Eye Solutions
Gels
Capsules & Tablets
Ophthalmology Therapeutics Segment by Application
Eye Infection
Glaucoma
Dry Eye Syndrome
Other
Ophthalmology Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmology Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmology Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmology Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ophthalmology Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ophthalmology Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ophthalmology Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ointments
- Eye Solutions
- Gels
- Capsules & Tablets
Applications
- Eye Infection
- Glaucoma
- Dry Eye Syndrome
- Other
Companies covered
- Teva Pharmaceutical Industries
- Novartis AG
- Pfizer
- Santen Pharmaceutical
- Bayer
- AbbVie
- Regeneron Pharmaceuticals
- Otsuka Holdings
- F. Hoffmann-La Roche
- Aerie Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ophthalmology Therapeutics Market Size (2021-2032)
- 2.2.2 Global Ophthalmology Therapeutics Sales (2021-2032)
- 2.2.3 Global Ophthalmology Therapeutics Market Average Price (2021-2032)
- 2.3 Ophthalmology Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ointments
- 2.3.3 Eye Solutions
- 2.3.4 Gels
- 2.3.5 Capsules & Tablets
- 2.4 Ophthalmology Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Eye Infection
- 2.4.3 Glaucoma
- 2.4.4 Dry Eye Syndrome
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ophthalmology Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ophthalmology Therapeutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Ophthalmology Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Ophthalmology Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Ophthalmology Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ophthalmology Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ophthalmology Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Ophthalmology Therapeutics, Established Date
- 3.9 Global Ophthalmology Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries
- 4.1.1 Teva Pharmaceutical Industries Company Information
- 4.1.2 Teva Pharmaceutical Industries Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ophthalmology Therapeutics Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Ophthalmology Therapeutics Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Ophthalmology Therapeutics Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Santen Pharmaceutical
- 4.4.1 Santen Pharmaceutical Company Information
- 4.4.2 Santen Pharmaceutical Business Overview
- 4.4.3 Santen Pharmaceutical Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Santen Pharmaceutical Ophthalmology Therapeutics Product Portfolio
- 4.4.5 Santen Pharmaceutical Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Ophthalmology Therapeutics Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 AbbVie
- 4.6.1 AbbVie Company Information
- 4.6.2 AbbVie Business Overview
- 4.6.3 AbbVie Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AbbVie Ophthalmology Therapeutics Product Portfolio
- 4.6.5 AbbVie Recent Developments
- 4.7 Regeneron Pharmaceuticals
- 4.7.1 Regeneron Pharmaceuticals Company Information
- 4.7.2 Regeneron Pharmaceuticals Business Overview
- 4.7.3 Regeneron Pharmaceuticals Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Regeneron Pharmaceuticals Ophthalmology Therapeutics Product Portfolio
- 4.7.5 Regeneron Pharmaceuticals Recent Developments
- 4.8 Otsuka Holdings
- 4.8.1 Otsuka Holdings Company Information
- 4.8.2 Otsuka Holdings Business Overview
- 4.8.3 Otsuka Holdings Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Otsuka Holdings Ophthalmology Therapeutics Product Portfolio
- 4.8.5 Otsuka Holdings Recent Developments
- 4.9 F. Hoffmann-La Roche
- 4.9.1 F. Hoffmann-La Roche Company Information
- 4.9.2 F. Hoffmann-La Roche Business Overview
- 4.9.3 F. Hoffmann-La Roche Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 F. Hoffmann-La Roche Ophthalmology Therapeutics Product Portfolio
- 4.9.5 F. Hoffmann-La Roche Recent Developments
- 4.10 Aerie Pharmaceuticals
- 4.10.1 Aerie Pharmaceuticals Company Information
- 4.10.2 Aerie Pharmaceuticals Business Overview
- 4.10.3 Aerie Pharmaceuticals Ophthalmology Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Aerie Pharmaceuticals Ophthalmology Therapeutics Product Portfolio
- 4.10.5 Aerie Pharmaceuticals Recent Developments
5 Global Ophthalmology Therapeutics Market Scenario by Region
- 5.1 Global Ophthalmology Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ophthalmology Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Ophthalmology Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Ophthalmology Therapeutics Sales by Region: 2027-2032
- 5.3 Global Ophthalmology Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Ophthalmology Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Ophthalmology Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Ophthalmology Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Ophthalmology Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ophthalmology Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Ophthalmology Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Ophthalmology Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Ophthalmology Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ophthalmology Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Ophthalmology Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Ophthalmology Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ophthalmology Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ophthalmology Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ophthalmology Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ophthalmology Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Ophthalmology Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ophthalmology Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Ophthalmology Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Ophthalmology Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ophthalmology Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ophthalmology Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ophthalmology Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Ophthalmology Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Ophthalmology Therapeutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Ophthalmology Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Ophthalmology Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Ophthalmology Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ophthalmology Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Ophthalmology Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ophthalmology Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Ophthalmology Therapeutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Ophthalmology Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Ophthalmology Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Ophthalmology Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ophthalmology Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Ophthalmology Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ophthalmology Therapeutics Value Chain Analysis
- 8.1.1 Ophthalmology Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ophthalmology Therapeutics Production Mode & Process
- 8.2 Ophthalmology Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ophthalmology Therapeutics Distributors
- 8.2.3 Ophthalmology Therapeutics Customers
9 Global Ophthalmology Therapeutics Analyzing Market Dynamics
- 9.1 Ophthalmology Therapeutics Industry Trends
- 9.2 Ophthalmology Therapeutics Industry Drivers
- 9.3 Ophthalmology Therapeutics Industry Opportunities and Challenges
- 9.4 Ophthalmology Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst